Endocrine Abstracts

Backgroud: When considering treatment of patients with severe osteoporosis (after previously failed antiresorptive treatment) or patients with glucocorticoid–induced osteoporosis, it is suitable to choose treatment by teriparatide (TPTD, rhPTH 1–34). In contrast to long–term treatment by bisphosphonates (BP) or denosumab (DMAB), the treatment with TPTD increases the volume of trabecular bone and the thickness of cortical bone. The recommended length of treatm...

Parathyroid hormone (PTH) has a biphasic effect on bone cells and can induce opposing responses resulting in both net bone loss and net bone formation. Patients with primary hyperparathyroidism (PHPT) lose the circadian rhythm for PTH and bone mass decreases. PTH administered intermittently resulting in increase in bone mass. We studied the differences in the circadian variability of bone turnover markers between women with PHPT and women with postmenopausal osteoporosis treat...